| Title |
Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer
|
|---|---|
| Published in |
OncoTargets and therapy, June 2015
|
| DOI | 10.2147/ott.s81939 |
| Pubmed ID | |
| Authors |
Yongchun Song, Zhiyong Yuan, Fengtong Li, Yang Dong, Hongqing Zhuang, Jingsheng Wang, Huaming Chen, Ping Wang |
| Abstract |
To evaluate the efficacy and safety of CyberKnife(®) treatment for locally-advanced pancreatic cancer (LAPC). The efficacy of CyberKnife(®) treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0-125.145 mL). The median prescribed dose was 45 Gy (35-50 Gy), delivered in 5 fractions (3-8 fractions). The overall survival (OS) rates and freedom from local progression (FFLP) rates were estimated using the Kaplan-Meier survival curve. The median follow-up for all patients was 10.9 months (3.2-48.7 months) and 15.6 months (3.9-37.6 months) among surviving patients. The median OS was 12.5 months, and the 1-year and 2-year survival rates were 53.9% and 35.1%, respectively. The 1-year FFLP rate was 90.8% based on the computed tomography (CT) evaluation. Grade 1-2 acute and late-stage gastrointestinal (GI) reactions were observed in 61% of the patients. One patient experienced grade 3 toxicity. Excellent clinical efficacy was obtained after treatment of LAPC using CyberKnife(®), with minimal toxicity. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 16% |
| Student > Ph. D. Student | 4 | 13% |
| Researcher | 4 | 13% |
| Student > Bachelor | 3 | 10% |
| Professor | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 7 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 48% |
| Engineering | 2 | 6% |
| Social Sciences | 2 | 6% |
| Physics and Astronomy | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 10 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#240,027
of 281,411 outputs
Outputs of similar age from OncoTargets and therapy
#49
of 71 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,411 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.